Beaufort Securities reissued their speculative buy rating on shares of ValiRx Plc (LON:VAL) in a report published on Wednesday morning. Beaufort Securities currently has a GBX 6.50 ($0.09) price objective on the stock.

ValiRx Plc (LON VAL) opened at 0.975 on Wednesday. The stock’s market cap is GBX 1.40 million. The stock has a 50 day moving average price of GBX 1.81 and a 200-day moving average price of GBX 2.14. ValiRx Plc has a 12 month low of GBX 0.96 and a 12 month high of GBX 11.49.

TRADEMARK VIOLATION NOTICE: “ValiRx Plc (VAL) Receives Speculative Buy Rating from Beaufort Securities” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at

About ValiRx Plc

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.